Avanafil
FDA-approved product (tablet, oral), marketed as Avanafil, Stendra.
- Registered studies
- 24
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Erectile dysfunction
- Impotence
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Drugs used in erectile dysfunction
- FDA pharmacologic class
- Phosphodiesterase 5 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
24registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Avanafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects
NCT00914511 · start 2009-05
Registered record
- Registry ID
- NCT00914511
- Conditions
- Avanfil ADME; Semen Exposure; Sperm Function
- Interventions
- avanafil 200mg; avanafil 200mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-05
- Completion
- 2009-06
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAvanfil ADME; Semen Exposure; Sperm FunctionInterventionavanafil 200mg; avanafil 200mgPhasePhase 1Registry statusCompletedResearch Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
NCT00895011 · start 2009-04
Registered record
- Registry ID
- NCT00895011
- Conditions
- Erectile Dysfunction
- Interventions
- Placebo; Avanafil; Avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-04
- Completion
- 2011-04
- Enrolment
- 298
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionPlacebo; Avanafil; AvanafilPhasePhase 3Registry statusCompletedLong-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
NCT00853606 · start 2009-03
Registered record
- Registry ID
- NCT00853606
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2010-04
- Enrolment
- 712
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionavanafilPhasePhase 3Registry statusCompletedTherapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil
NCT00903981 · start 2009-03
Registered record
- Registry ID
- NCT00903981
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil; Avanafil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2009-11
- Enrolment
- 208
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil; Avanafil; PlaceboPhasePhase 3Registry statusCompletedResearch Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
NCT00809471 · start 2008-12
Registered record
- Registry ID
- NCT00809471
- Conditions
- Erectile Dysfunction
- Interventions
- placebo; avanafil; avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2010-02
- Enrolment
- 390
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionplacebo; avanafil; avanafilPhasePhase 3Registry statusCompletedResearch Evaluating an Investigational Medication for Erectile Dysfunction - General ED
NCT00790751 · start 2008-11
Registered record
- Registry ID
- NCT00790751
- Conditions
- Erectile Dysfunction
- Interventions
- placebo; avanafil; avanafil; avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-11
- Completion
- 2009-08
- Enrolment
- 646
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionplacebo; avanafil; avanafil; avanafilPhasePhase 3Registry statusCompletedA Thorough EKG Safety Study of TA-1790 (Avanafil)
NCT00769041 · start 2008-10
Registered record
- Registry ID
- NCT00769041
- Conditions
- Erectile Dysfunction
- Interventions
- moxifloxacin; avanafil; avanafil; sugar pill
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2009-01
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionmoxifloxacin; avanafil; avanafil; sugar pillPhasePhase 1Registry statusCompletedTo Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil
NCT00770042 · start 2008-10
Registered record
- Registry ID
- NCT00770042
- Conditions
- Erectile Dysfunction
- Interventions
- Ritonavir; Ketoconazole; Erythomycin; Avanafil; Avanafil; Avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2008-12
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionRitonavir; Ketoconazole; Erythomycin; Avanafil +2 morePhasePhase 1Registry statusCompletedEfficacy and Safety of Avanafil in the Patients With Erectile Dysfunction
NCT02477436 · start 2008-02
Registered record
- Registry ID
- NCT02477436
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2008-09
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil; PlaceboPhasePhase 2Registry statusCompleted